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Abstract
Patients with von Hippel-Lindau (VHL) disease develop tumors in a range of tissues, but existing mouse
models of Vhlh mutation have failed to reproduce these lesions. Epididymal cystadenomas arise
frequently in VHL patients, but VHL mutation alone is believed to be insufficient for tumor formation,
implying a requirement for cooperating mutations in epididymal pathogenesis. Here we show that
epididymal cystadenomas from VHL patients frequently also lack expression of the PTEN tumor
suppressor and display activation of phosphatidylinositol 3-kinase (PI3K) pathway signaling. Strikingly,
while conditional inactivation of either Vhlh or Pten in epithelia of the mouse genital tract fails to
produce a tumor phenotype, their combined deletion causes benign genital tract tumors with regions of
squamous metaplasia and cystadenoma. The latter are histologically identical to lesions found in VHL
patients. Importantly, these lesions are characterized by expansion of basal stem cells, high levels of
expression and activity of HIF1alpha and HIF2alpha, and dysregulation of PI3K signaling. Our studies
suggest a model for cooperative tumor suppression in which inactivation of PTEN facilitates epididymal
cystadenoma genesis initiated by loss of VHL.
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Patients with von Hippel-Lindau (VHL) disease develop tumors in a range of tissues, but existing mouse
models of Vhlh mutation have failed to reproduce these lesions. Epididymal cystadenomas arise frequently in
VHL patients, but VHL mutation alone is believed to be insufficient for tumor formation, implying a require-
ment for cooperating mutations in epididymal pathogenesis. Here we show that epididymal cystadenomas from
VHL patients frequently also lack expression of the PTEN tumor suppressor and display activation of
phosphatidylinositol 3-kinase (PI3K) pathway signaling. Strikingly, while conditional inactivation of either
Vhlh or Pten in epithelia of the mouse genital tract fails to produce a tumor phenotype, their combined deletion
causes benign genital tract tumors with regions of squamous metaplasia and cystadenoma. The latter are
histologically identical to lesions found in VHL patients. Importantly, these lesions are characterized by
expansion of basal stem cells, high levels of expression and activity of HIF1 and HIF2, and dysregulation
of PI3K signaling. Our studies suggest a model for cooperative tumor suppression in which inactivation of
PTEN facilitates epididymal cystadenoma genesis initiated by loss of VHL.
Inheritance of a mutant allele of the von Hippel-Lindau
(VHL) tumor suppressor gene results in the VHL familial
cancer syndrome, in which patients are predisposed to develop
a variety of tumors, including central nervous system and ret-
inal hemangioblastomas, endolymphatic sac tumors, phaeo-
chromocytomas, pancreatic microcystic adenomas, neuroendo-
crine tumors, clear cell renal cell carcinomas, epididymal
cystadenomas in males, and broad ligament cystadenomas
(also known as APMO [adnexal papillary cystadenoma of
probable mesonephric origin]) in females (15, 21). The last two
tumor types occur in tissues that derive from the embryonic
mesonephric duct (also called the Wolffian duct), suggesting
that similar genetic events may underlie tumorigenesis in these
two tissues.
While epididymal cystadenomas are benign lesions that oc-
cur very rarely in the general population, macroscopic lesions
arise in approximately 50% of male VHL patients (4), and it is
believed that microscopic lesions may be present in almost all
male VHL patients (9). These lesions are characterized by
deletions or mutations of the remaining wild-type VHL allele
(7, 9, 38). Consistent with the known role of pVHL as a com-
ponent of a ubiquitin ligase complex that targets the hypoxia-
inducible factor  (HIF) transcription factors for normoxic
proteolytic degradation (26), epididymal cystadenomas display
accumulation of HIF1 and HIF2, as well as high levels of
expression of the HIF-inducible proteins CA9, GLUT-1, and
vascular endothelial growth factor (VEGF) (9, 20). Similar to
conclusions drawn from analysis of other tumor-prone tissues
in VHL patients (8, 25, 47, 48), mutational inactivation of VHL
alone appears to be insufficient to cause the formation of an
epididymal cystadenoma. Rather, while small VHL mutant le-
sions are detected frequently within the efferent ductules of
VHL patients, frank cystadenomas occur relatively rarely (9).
One interpretation of this result is that additional mutations
may be required for tumor progression.
The phosphatase and tensin homologue (PTEN) tumor sup-
pressor gene is mutated at high frequency in many different
tumor types, and patients that inherit a mutant allele of PTEN
(Cowden’s disease) are predisposed to develop multiple
hamartomatous and mucocutaneous lesions and are at in-
creased risk of developing diverse neoplasms (reviewed in
reference 2). Among other functions, PTEN acts as a lipid
phosphatase to dephosphorylate phosphatidylinositol 3,4,5-
triphosphate that is formed as a result of the activity of phos-
phatidylinositol 3-kinase (PI3K) enzymes (24). PTEN thereby
opposes signal transduction by numerous cell surface recep-
tors. Inactivation of PTEN results in constitutive activation of
multiple signaling cascades that are activated by PI3K, AKT,
mTOR, S6K, and c-Jun N-terminal kinases (2, 46) and leads to
alteration of transcriptional programs that are controlled by
FOXO family and Jun family transcription factors (1, 46). In
general, loss of PTEN function and constitutive signaling via
the PI3K signaling pathway result in cellular proliferation.
Here we demonstrate that loss of PTEN expression and
activation of PI3K signaling occur frequently in epididymal
cystadenomas from human VHL patients. While the individual
deletion of Vhlh or Pten in genital epithelia of mice causes a
relatively mild phenotype, Vhlh Pten double mutant mice de-
velop tumors that contain regions of clear cell cystadenoma
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that mimic the epididymal clear cell cystadenomas that de-
velop in human VHL patients. These studies highlight a novel
cooperative genetic interaction with respect to tumor suppres-
sion by Vhlh and Pten.
MATERIALS AND METHODS
VHL patient epididymal cystadenomas. Two paraffin-embedded epididymal
cystadenoma biopsies from VHL patients were previously described (9), and one
sample was obtained from the pathology collection of the French VHL Group.
Mouse genetics. C57BL/6J Ksp1.3-Cre mice (37) were obtained from Peter
Igarashi (UT Southwestern), BALB/c;129S mixed-background Vhlhfl/fl mice (12)
were obtained from The Jackson Laboratory, and BALB/c Ptenfl/fl mice (18) were
obtained from Andreas Trumpp (ISREC, Switzerland). Ksp1.3-Cre/ mice were
intercrossed with Vhlhfl/fl; Ptenfl/fl mice to generate Ksp1.3-Cre/; Vhlhfl/;
Ptenfl/ and /; Vhlhfl/; Ptenfl/ mice. These mice were subsequently inter-
crossed to provide sets of parents (that contained genetic contributions from all
of the different strain backgrounds) from which Ksp1.3-Cre/; Vhlhfl/fl; Pten/
(Vhlh/), Ksp1.3-Cre/; Vhlh/; Ptenfl/fl (Pten/), and Ksp1.3-Cre/; Vhlhfl/fl;
Ptenfl/fl (Vhlh/ Pten/) mice were generated. Littermate mice that lacked the
Ksp1.3-Cre transgene were used as controls. B6.129S4-Gt(ROSA)26Sortm1Sor/J
mice (ROSA26R mice) were obtained from The Jackson Laboratory. Mouse
embryo fibroblasts were derived from embryonic day 13.5 wild-type (C57BL/6J
background), Vhlhfl/fl, Ptenfl/fl, and Vhlhfl/fl; Ptenfl/fl mice by using standard tech-
niques and were infected with high-titer adenovirus expressing Cre recombinase
(17).
Immunohistochemistry and X-Gal staining. Immunohistochemistry was per-
formed as previously described (45), using the following antibodies: anti-CA9
(M75) (31), anti-involucrin (SY5; Sigma), anti-keratin 6 (PRB-169P; Covance),
anti-keratin 14 (PRB-155P; Covance), anti-Notch4 (sc-5594; Santa Cruz Biotech-
nology), anti-p63 (clone 4A4; Lab Vision), anti-PTEN (9559; Cell Signaling
Technology), anti-phospho-Ser240/244 S6 ribosomal protein (2215; Cell Signal-
ing Technology), anti-phospho-Ser65 4E-BP1 (9451; Cell Signaling Technology),
anti-von Willebrand factor (F3520; Sigma), and anti-mouse pVHLCT (45). Im-
munohistochemistry using anti-HIF1 (NB100-105; Novus Biologicals) and anti-
HIF2 (PM8) (34) antibodies was performed using a Dako Cytomation catalyzed
signal amplification system. X-Gal (5-bromo-4-chloro-3-indolyl--D-galacto-
pyranoside) staining was performed on 50-m-thick cryosections of freshly
frozen tissue as previously described (37).
Western blotting. Whole epididymal protein extracts were prepared by pow-
dering freshly frozen epididymis under liquid nitrogen, followed by homogeni-
zation in TNN buffer (25 mM Tris-HCl, pH 7.2, 150 mM sodium chloride, 10%
glycerol, 1% NP-40, 10 mM sodium fluoride, 1 mM Na3VO4, 1 mM phenylmeth-
ylsulfonyl fluoride, 1 mM dithiothreitol, 10 g/ml aprotinin). Thirty to 60 g of
boiled protein extract was run in 8 to 15% acrylamide gels, transferred to
nitrocellulose membranes, and visualized by immunoblotting with the following
antibodies: anti-phospho-Ser473-AKT (4058; Cell Signaling Technology), anti-
AKT (sc-1619; Santa Cruz), anti-phospho-Thr202/Tyr204 ERK1/2 (9101; Cell
Signaling Technology), anti-phospho-Ser9 GSK3 (2215; Cell Signaling Tech-
nology), anti-HIF2 (PM8) (34), anti-LDH-A (sc-27230; Santa Cruz), anti-
PTEN (sc-7974; Santa Cruz), anti-phospho-Ser240/244 S6 ribosomal protein
(2215; Cell Signaling Technology), anti-S6 ribosomal protein (2212; Cell Signal-
ing Technology), and anti-mouse pVHLCT antibody (45). To detect GLUT-1
using anti-GLUT-1 antibody (ab14683; Abcam), protein lysates were not boiled
prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Real-time PCR analysis. Total RNA was prepared from powdered tissue by
use of an RNeasy minikit (Qiagen), and cDNA was prepared using random
hexanucleotide primers and Ready-to-Go You-Prime first-strand beads (GE
Healthcare). Genomic DNA was isolated by digesting powdered tissue overnight
at 55°C in buffer containing 500 mg/ml proteinase K, 1% sodium dodecyl sulfate,
50 mM EDTA, 150 mM NaCl, and 10 mM Tris-HCl, pH 7.5, followed by
phenol-chloroform treatment and precipitation with isopropanol. Real-time
PCR analysis of cDNA and genomic DNA was conducted using Absolute Sybr
green (Abgene) and the following primer pairs: for TAp63, 5GTGGATGAAC
CTTCCGAAAA3 and 5GAGGAGCCGTTCTGAATCTG3; for Np63, 5C
AAAACCCTGGAAGCAGAAA3 and 5 GAGGAGCCGTTCTGAATCTG
3; for Glut-1, 5GCTTATGGGCTTCTCCAAACT3 and 5GGTGACACCTC
TCCCACATAC3; for Vegf-a, 5CTTGTTCAGAGCGGAGAAAGC3 and 5
ACATCTGCAAGTACGTTCGTT3; for Delta-1, 5CAGGACCTTCTTTCGC
GTATG3 and 5AAGGGGAATCGGATGGGGTT3; for Jag-2, 5GCGACC
AGTACGGCAACAA3 and 5GGGACACACTCGTCACAGAA3; for Hes-1,
5CCAGCCAGTGTCAACACGA3 and 5AATGCCGGGAGCTATCTTTCT
3; for Hey-1, 5GTCTCCCATCTCAACAACTACG3 and 5GTGTGGGTGA
TGTCCGAAGG3; for Hey-2, 5CAATTCACCGACAACTACCTCTC3 and
5GCCTTTTCTAACTTGGCAGATCC3; for 18S rRNA, 5TGGCCGACCAT
AAACGATGCC3 and 5TGGTGGTGCCCTTCCGTCAAT3; for the Vhlh
locus, 5ACAGTAGGACCACATGAAGATAGG3 and 5TCGAGCTTTACC
CACCTCTCTAG3; and for the p63 locus, 5GAGGAGCCGTTCTGAATC
TG3 and 5TAATGCCAATTTTATTGAGC3.
RESULTS
Loss of PTEN expression in epididymal cystadenomas in
VHL patients. To investigate pathways that may contribute to
the development of human epididymal cystadenoma, we iden-
tified 15 microscopic VHL mutant clear cell papillary cystade-
nomas in epididymal biopsies from three patients with VHL
disease. The lesions stained positively for the HIF target gene
CA9 (Fig. 1A) (9). While the tumor suppressor protein PTEN
was detected by immunostaining in normal epididymal tubules
that lacked expression of CA9 (Fig. 1B), its expression was
reduced or absent in tumor cells of 11 of 15 cystadenomas (Fig.
1C) but maintained in the stromal tissue of these tumors, likely
due to the absence of mutations in the stroma. Since PTEN
FIG. 1. Activation of PI3K pathway signaling in VHL patient epi-
didymal cystadenomas. Immunohistochemical staining of an epididy-
mal section from a VHL patient is shown. (A) VHL-negative cells were
identified by staining with an antibody against CA9. (B, D, and F)
Staining of normal epididymal tubules from the region shown by the
upper left box in panel A. (C, E, and G) Staining of a region of
VHL-negative epididymal cystadenoma from the region shown by the
lower right box in panel A. Antibodies against PTEN (B and C),
phospho-Ser240/244 ribosomal S6 protein (D and E), or phospho-
Ser65 4E-BP1 (F and G) were used for staining. Panels B to G are at
the same magnification. Bars, 100 m.
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negatively regulates signaling by the PI3K-AKT-mTOR signal-
ing pathway, we examined the expression of downstream mark-
ers of activation of this pathway in VHL patient epididymal
cystadenomas. In comparison to normal tubules, tumors exhib-
ited increased staining for phospho-Ser240/244 S6 ribosomal
protein (Fig. 1D and E) and for phospho-Ser65 4E-BP1 (Fig.
1F and G), consistent with the idea that the PI3K signaling
pathway is hyperactivated in these lesions. Thus, mechanisms
that lead to loss or reduction of the PTEN protein and/or
activation of PI3K pathway signaling may be involved in the
formation of cystadenomas in VHL patients.
Cystadenoma and squamous metaplasia following Vhlh and
Pten deletion. To test this hypothesis and to model the genetic
changes that occur in human cystadenoma, mice were gener-
ated in which Vhlh and Pten were deleted singly and in
combination in epithelial cells of the genital tract by crossing
Vhlhfl/fl and Ptenfl/fl mice to Ksp1.3-Cre transgenic mice (37). In
addition to expression in the kidney, this transgene directs Cre
recombinase expression to the Wolffian and Mu¨llerian ducts of
the mesonephros during embryonic development (37). The
Wolffian duct gives rise to the epididymis, vas deferens, and
vesicular glands in males, and the Mu¨llerian duct gives rise to
the oviducts, uterus, and cervix in females (51). X-Gal staining
of mice carrying the Ksp1.3-Cre transgene and a ROSA26 Cre
reporter transgene (ROSA26R) (40), in which transcription of
the lacZ gene occurs only after Cre-mediated excision of a
loxP-flanked transcriptional termination sequence, confirmed
that the Ksp-1.3 transgene directs Cre activity to the epithelia
of genital tissues (Fig. 2). Western blotting of epididymal tissue
demonstrated that Ksp1.3-Cre efficiently reduced the expres-
sion of pVHL and PTEN proteins (see Fig. 10L). These mice
displayed a range of striking phenotypes in tissues of the male
and female genital tracts.
In Ksp1.3-Cre; Vhlhfl/fl mice (hereafter referred to as Vhlh/
mice), the male and female genital tracts appeared morpho-
logically and histologically normal (Fig. 3D and H; 4B, F, and
J; and 5D), with the exception of increased vascularization, as
shown by the aberrant presence of dilated blood capillaries
surrounding epididymal tubules (Fig. 3H and 4B, arrowheads).
Staining using an antibody against the endothelial cell marker
von Willebrand factor confirmed that these structures repre-
sent blood vessels (Fig. 6B). This finding is consistent with the
known role of VHL inactivation in promoting angiogenesis and
with the elevated levels of Vegf-a mRNA in this tissue of
Vhlh/ mice (see Fig. 10K). Moreover, these findings are also
consistent with the results of analysis of human VHL epidid-
ymal tissue that argue that loss of VHL alone causes neoan-
giogenesis but is not sufficient to cause formation of cystade-
noma (9).
Genital tissues of Ksp1.3-Cre; Ptenfl/fl mice (hereafter
referred to as Pten/ mice) were enlarged (Fig. 3E and data
not shown). Epithelial hyperplasia was observed in the epidid-
ymis (Fig. 3I and 4C), vesicular glands (Fig. 4G), and vas
deferens (Fig. 4K) in male mice. Mice aged up to 1 year did not
show any tumor formation, demonstrating that the loss of Pten
alone is not sufficient to cause transition from epithelial hy-
perplasia to a tumorigenic state. Female Pten/ mice dis-
played hyperplasia of the endometrial glands and lumen (Fig.
5E), similar to the phenotypes that arise in this tissue in
Pten/ mice (33, 41). Endometrial hyperplasia was accompa-
nied by partial squamous differentiation, as demonstrated by
the expression of keratin 14 (K14) (Fig. 7C), which normally is
expressed in basal layer keratinocytes that maintain prolifera-
tive capacity, and of keratin 6 (K6) (Fig. 7G), which is ex-
pressed by proliferating keratinocytes during wound healing
and in culture (6). These lesions lacked expression of involu-
crin (Fig. 7K), a component of cornified epithelia and a marker
of terminally differentiated keratinocytes (5).
In contrast to the relatively mild phenotypes of Vhlh/ and
Pten/ single mutant mice, all Ksp1.3-Cre; Vhlhfl/fl; Ptenfl/fl
(hereafter referred to as Vhlh/ Pten/ mice) double mutant
mice developed benign mixed adenosquamous genital tract
tumors. In 8-week-old male mice, genital tissues were notice-
ably enlarged (Fig. 3F and data not shown), and by 14 weeks of
age, the entire genital tract was grossly deformed (Fig. 3B).
Histological analysis of tumors in the epididymis (Fig. 3J and
4D), vesicular glands (Fig. 4H), and vas deferens (Fig. 4L)
revealed gross disorganization of tissue morphology. Strik-
ingly, tumors contained regions of cystadenoma characterized
FIG. 2. Ksp1.3-Cre directs Cre-mediated recombination to epithe-
lia of the male and female genital tracts. The images show X-Gal
staining of epididymal tubules (A and B), vas deferens (C and D),
vesicular gland (E and F), endometrial lumen (G and H), and endo-
metrial glands (I and J) from transgenic mice containing the ROSA26R
Cre reporter transgene (A, C, E, G, and I) or containing Ksp1.3-Cre
and ROSA26R transgenes (B, D, F, H, and J). All panels are the same
magnification. Bar, 50 m.
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by adenoid structures (Fig. 3J) that were histologically identi-
cal to the cystadenoma lesions that arise in the epididymides of
VHL patients. Consistent with the role of pVHL in suppress-
ing angiogenesis, epididymal cystadenomas exhibited a highly
vascularized stromal component (Fig. 6D). Epididymal cysta-
denomas and renal cell carcinomas in VHL patients are char-
acterized by clear cell morphology, which results from the
accumulation of lipids and glycogen, which prevent staining by
the cytoplasmic dye eosin. Similarly, regions of cystadenoma in
Vhlh/ Pten/ mice displayed clear cell morphology (Fig.
3K).
Intermingled with regions of cystadenoma in Vhlh/ Pten/
mice were regions of squamous differentiation (Fig. 3J and L)
that recapitulate epidermal differentiation. Evidence for this
conclusion includes hematoxylin and eosin staining that re-
vealed the presence of a multilayered epidermis-like structure,
blue-staining keratin droplets in terminally differentiated cells
(Fig. 3M, arrowheads), and pink-staining secreted keratin fi-
bers (Fig. 3M, arrows). Immunohistochemical staining for the
expression of the squamous differentiation markers K14, K6,
and involucrin (Fig. 8J and 9D and I) confirmed that lesions in
Vhlh/ Pten/ mice express markers of proliferating and ter-
minally differentiated keratinocytes. In contrast, regions of cys-
tadenoma did not display markers of squamous differentiation
(Fig. 9E and J).
Immunohistochemical staining using antibodies against
pVHL (Fig. 3O to Q) and PTEN (Fig. 3R to T) confirmed the
deletion of both genes in regions of cystadenoma and squa-
mous metaplasia. In the epididymides of 8-week-old mice, we
could identify discrete sites that presumably represent the ear-
FIG. 3. Phenotypic analysis of Vhlh and Pten deletion in the male genital tract. (A and B) Genital tracts of 14-week-old male wild-type (A) and
Vhlh/ Pten/ (B) mice. (C to F) Epididymides and vasa deferentia of 8-week-old wild-type (C), Vhlh/ (D), Pten/ (E), and Vhlh/ Pten/
(F) mice. (G to J) Hematoxylin- and eosin-stained sections of epididymides of 8-week-old wild-type (G), Vhlh/ (H), Pten/ (I), and Vhlh/
Pten/ (J) mice. Arrowheads in panel H point to blood vessels, regions between arrows in panel I highlight regions of hyperplasia, arrowheads
in panel J point to adenoid structures in a region of cystadenoma, and arrows in panel J point to a region of squamous differentiation. (K) Region
of cystadenoma in the epididymis of a 14-week-old Vhlh/ Pten/ mouse with examples of clear cells shown by arrowheads. (L) Epididymal tubule
showing squamous metaplasia in a 14-week-old Vhlh/ Pten/ mouse. (M) Zoom of the dotted boxed region in panel L. (N) Early lesion in an
epididymal tubule of an 8-week-old Vhlh/ Pten/ mouse. A region that appears to be a precursor of cystadenoma is labeled CA, and a region
of cells undergoing squamous metaplasia is labeled SM. (O to Q) Immunohistochemical staining using an antibody against pVHL in epididymal
tubules from a wild-type (O) mouse or from regions of cystadenoma (P) and squamous metaplasia (Q) from a Vhlh/ Pten/ mouse. (R to T)
Immunohistochemical staining using an antibody against Pten in epididymal tubules from a wild-type (R) mouse or from regions of cystadenoma
(S) and squamous metaplasia (T) from a Vhlh/ Pten/ mouse. Panels O to T are at the same magnification. Bars, 50 m.
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liest stage of development of these lesions. Regions of cysta-
denoma and squamous differentiation appear to coarise within
otherwise morphologically normal epididymal tubules. Re-
gions that are apparently precursors of cystadenoma occur at
the basal surface of the tubule (Fig. 3N, area labeled CA), and
layers of cells that are undergoing squamous differentiation
overlie these cystadenoma precursors and project toward the
center of the epididymal tubule (Fig. 3N, area labeled SM).
Thus, regions of cystadenoma and squamous differentiation
appear to arise at the same site.
Tumor phenotypes were also observed in the genital tracts
of female Vhlh/ Pten/ mice (Fig. 5B), including hyperplasia
and full squamous differentiation of the uterine endometrial
lumen (Fig. 5F and 7D, H, and L), endometrial hyperplasia
(Fig. 5G), and endometrial hyperplasia with cyst formation
(Fig. 5H). The latter histologically resembles the cystadenoma
and cystic lesions seen in the broad ligament in human female
VHL patients. Cysts and squamous epithelial hyperplasia also
occurred in the cervixes and oviducts of Vhlh/ Pten/ mice
(data not shown).
Genital tracts of Vhlh/ Pten/ mice were indistinguishable
from those of wild-type mice. In contrast, the genital tracts of
Vhlh/ Pten/ and Vhlh/ Pten/ mice were initially indistin-
guishable from those of Vhlh/ and Pten/ mice, respectively,
but by 6 months of age these mice developed histologically iden-
tical lesions to those seen in Vhlh/ Pten/ mice (data not
shown). However, whereas Vhlh/ Pten/ mice developed tu-
mors simultaneously in all genital tract epithelia, tumors arose
only at discrete sites in Vhlh/ Pten/ and Vhlh/ Pten/ mice.
Therefore, it is likely that these tumors arose due to somatic
mutation of the remaining wild-type Vhlh or Pten allele.
In summary, genital tract lesions seen in Vhlh/ Pten/
FIG. 4. Histological analysis of Vhlh and/or Pten deletion in the male genital tract. (A to D) Sections of caput epididymides from 14-week-old
wild-type (A), Vhlh/ (B), Pten/ (C), and Vhlh/ Pten/ (D) mice. Bar, 200 m. (E to H) Sections of vesicular glands from 8-week-old wild-type
(E), Vhlh/ (F), Pten/ (G), and Vhlh/ Pten/ (H) mice. Bar, 200 m. (I to L) Sections of vasa deferentia from 11-week-old wild-type (I),
Vhlh/ (J), Pten/ (K), and Vhlh/ Pten/ (L) mice. Bar, 20 m.
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mice recapitulate the clear cell cystadenoma lesions that are
found in male and female human VHL patients. Squamous
metaplasia, however, is not a clinical feature of human VHL
disease.
Expansion of basal cells in tumors in Vhlh/ Pten/ mice.
Pseudostratified epithelia of the genitourinary tract, including
the epididymal tubules, vesicular glands, vas deferens, pros-
tate, and urothelium, are lined by a population of p63-express-
ing basal cells (13, 36). While the functions of basal cells are
incompletely characterized for most tissues, detailed studies of
the prostate have shown that basal cells act as progenitor cells
that are necessary for prostatic development (10). Based on
these findings and the findings that p63-expressing basal cells
are important for the formation of other epithelia, including
the epidermis and salivary, lachrymal, and mammary glands
(27, 52), it is believed that basal cells may function in adult
tissues as progenitor or stem cell-like cells that have the ca-
pacity to self-renew as well as to differentiate into different
lineages and which thereby act to maintain epithelia (reviewed
in reference 10). This idea, however, remains to be proven
formally.
To gain insight into the molecular changes that cause normal
genital tract epithelia to be reprogrammed to form cystadeno-
mas and epidermis-like structures in Vhlh/ Pten/ mice, we
focused further analysis on the epididymis. Since deletion of
Pten within the prostatic epithelium caused expansion of basal
cells (49), we analyzed expression of the basal cell markers p63
and K14 (49, 50) in the epididymis. This analysis revealed that
epididymal tubules in Vhlh/ mice (Fig. 8B and G) and
Pten/ mice (Fig. 8C and H) contained normal and slightly
increased numbers of basal cells, respectively. In Vhlh/ mice,
the pattern of staining of basal cells appears distorted by the
FIG. 5. Phenotypic analysis of Vhlh and Pten deletion in the female genital tract. (A and B) Genital tracts of 20-week-old female wild-type
(A) and Vhlh/ Pten/ (B) mice. Note the thickened uterus and presence of an ovarian duct tumor in panel B. (C to H) Hematoxylin- and
eosin-stained sections of uteri of 20-week-old wild-type (C), Vhlh/ (D), Pten/ (E), and Vhlh/ Pten/ (F to H) mice. (F) Region of squamous
metaplasia of the endometrial lumen; (G) region of hyperplasia of endometrial glands; (H) endometrial hyperplasia with cyst formation. Bars,
50 m.
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presence of capillaries associated with the tubules (Fig. 8G,
arrowheads). In Pten/ mice, basal cells were not restricted to
the basal layer of tubules but were present within regions of
hyperproliferation (Fig. 8C and H, arrows). This finding is
consistent with the role of PTEN as a regulator of cell migra-
tion (19). Mislocalization of basal cells may contribute to the
altered architecture of epithelia in Pten/ mice. In contrast to
the relatively mild alteration in basal cell number and local-
ization in Vhlh/ and Pten/ mice, dramatically increased
numbers of cells that stained positively for p63 and K14 were
observed throughout regions of cystadenoma (Fig. 8D and I)
and squamous metaplasia (Fig. 8E and J) in the epididymides
of Vhlh/ Pten/ mice.
p63 exists as two isoforms, Np63 and TAp63, that are
generated by alternate promoters. Np63 is the isoform that is
expressed in basal cells in genital tract epithelia (13, 36) and
has been shown to be necessary for the development of epi-
thelial tissues (42). Consistent with these findings, real-time
PCR analysis demonstrated that Np63, not TAp63, is the
isoform that is expressed by the expanded pool of basal cells in
FIG. 6. Increased vascularization in epididymides of Vhlh/ and Vhlh/ Pten/ mice. (A to D) Immunohistochemical staining for the
endothelial cell marker von Willebrand factor in epididymides of littermate 11-week-old wild-type (A), Vhlh/ (B), Pten/ (C), and Vhlh/
Pten/ (D) mice. All panels are the same magnification. Bar, 100 m.
FIG. 7. Squamous differentiation in endometrial lumen of Pten/ and Vhlh/ Pten/ mice. Shown is immunohistochemical staining for K14
(A to D), K6 (E to H), and involucrin (I to L) in endometrial lumina of wild-type (A, E, and I), Vhlh/ (B, F, and J), Pten/ (C, G, and K), and
Vhlh/ Pten/ (D, H, and L) mice. All panels are the same magnification. Bar, 50 m.
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the epididymides of Vhlh/ Pten/ mice (Fig. 8K). Real-time
quantitative PCR analysis of genomic DNA demonstrated that
the increased expression of Np63 mRNA does not result
from amplification of the p63 gene (Fig. 8L).
Collectively, these findings suggest that an expansion of
basal cells may underlie tumor formation in genital epithelia in
Vhlh/ Pten/ mice. Cystadenomas appear to result from
basal cell proliferation without differentiation, whereas regions
of squamous metaplasia contain abundant basal cells in basal
layers but also cells that express markers of epidermal differ-
entiation in overlying layers of cells. Thus, combined loss of
Vhlh and Pten must alter molecular signaling cascades that
influence the proliferation and differentiation of basal cells.
Elevated HIF activity in tumors in Vhlh/ Pten/ mice.
To investigate such potential molecular changes, we first ana-
lyzed the status of activation of the HIF pathway. Consistent
with the known role of pVHL in degrading HIF transcription
factors, immunohistochemical staining revealed strong nuclear
accumulation of HIF1 in epididymal tubules in Vhlh/ mice
(Fig. 10B) and in regions of cystadenoma (Fig. 10D) and squa-
mous metaplasia (Fig. 10E) in Vhlh/ Pten/ mice but not in
tubules from wild-type or Pten/ mice (Fig. 10A and C). While
nuclear staining for HIF2 was observed even in wild-type and
Pten/ mice (Fig. 10F and H), Vhlh/ (Fig. 10G) and Vhlh/
Pten/ (Fig. 10I and J) mice displayed more intense staining.
Upregulation of HIF2 in epididymal tissues of Vhlh/ and
Vhlh/ Pten/ mice was confirmed by Western blotting (Fig.
10L). Surprisingly, the extent of upregulation of HIF2 in
Vhlh/ Pten/ mice was less than that in Vhlh/ mice, sug-
gesting that a loss of PTEN activity may alter the balance of
expression of HIF family members in response to loss of
pVHL. HIF1 was not detectable by Western blotting using
three commercially available antibodies. Real-time quantita-
tive PCR analysis of the HIF-inducible genes Glut-1 and
Vegf-a (Fig. 10K) and Western blotting for the HIF-inducible
proteins GLUT-1 and LDH-A (Fig. 10L) confirmed that HIF
activity is induced by Vhlh and by Vhlh Pten gene deletion. The
trend toward increased HIF target gene abundance in the
epididymides of Vhlh/ Pten/ mice in comparison to those
of Vhlh/ mice likely reflects the expansion of Vhlh-negative
cells in Vhlh/ Pten/ tumors. In summary, since Vhlh/
mouse epididymides display abundant HIF activity but do not
FIG. 8. Expansion of basal cells in epididymal tumors in Vhlh/ Pten/ mice. (A to J) Immunohistochemical staining for p63 (A to E) and K14
(F to J) in epididymal tubules of 8-week-old wild-type (A and F), Vhlh/ (B and G), Pten/ (C and H), and Vhlh/ Pten/ (D, E, I, and J) mice.
Panels D and I display regions of cystadenoma (CA), and panels E and J display regions of squamous metaplasia (SM). Arrows in panel C highlight
p63-positive cells that are not localized to the basal layer, and arrowheads in panel E show examples of terminally differentiated cells that do not
express p63. Arrowheads in panel G highlight small blood vessels, and arrows in panel H highlight K14-positive cells that are not localized to the
basal layer. Panels A to J are all at the same magnification. Bar, 50 m. (K) Real-time quantitative PCR analysis of mRNA expression in
epididymides from 8- to 14-week-old wild-type, Vhlh/, Pten/, and Vhlh/ Pten/ mice, using isoform-specific primers for TAp63 and Np63.
Expression changes were normalized against the expression level of the 18S rRNA. Data represent means  standard deviations (n 	 2) or
means  ranges (n 
 2). Each sample was analyzed in triplicate. (L) Real-time quantitative PCR analysis of epididymal genomic DNAs from
wild-type (n 
 1) and Vhlh/ Pten/ (n 
 2) mice, using primers that detect intronic regions of the p63 and Vhlh genes (the latter region lies
outside the loxP-flanked sequences and is not deleted by Cre). The ratio of p63 to Vhlh gene abundance is presented as the mean  range. Each
sample was analyzed in triplicate.
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develop tumors, we conclude that tumor formation in Vhlh/
Pten/ mice must involve pathways in addition to HIF.
Vhlh influences downstream signaling following Pten dele-
tion. Since the PI3K signaling pathway promotes the prolifer-
ation and prevents the differentiation of stem cells and pro-
genitor cells (reviewed in reference 44) and since tumors of
Vhlh/ Pten/ mice contain an expansion of basal cells, we
investigated the activation status of the PI3K signaling cascade
in epididymal tissue following Vhlh and/or Pten deletion. As
expected, deletion of Pten alone or Pten and Vhlh together, but
not of Vhlh alone, led to accumulation of phospho-Ser473-
AKT, indicative of activation of PI3K (Fig. 11A). However,
phospho-Ser240/244-S6 ribosomal protein, a downstream
marker of mTOR and p70S6K activation, accumulated only in
Vhlh/ Pten/ mice, not in Pten/ mice (Fig. 11A). This
effect appears to be specific to S6 ribosomal protein, as Ser9
phosphorylation of glycogen synthase kinase 3 (GSK3; a site
targeted by AKT) and Thr202/Tyr204 phosphorylation of
ERK1/2 were not altered by Vhlh and Pten deletion (Fig. 11A).
Immunohistochemical staining confirmed that phospho-Ser240/
244-S6 ribosomal protein expression is dysregulated in preneo-
plastic epididymal epithelium of Vhlh/ Pten/ (Fig. 11E)
mice but not in Vhlh/ (Fig. 11C) or Pten/ (Fig. 11D) mice.
Phospho-Ser240/244-S6 ribosomal protein expression is also
dysregulated in regions of cystadenoma and is highly upregu-
lated in regions of squamous metaplasia (Fig. 11F). The mech-
anism that underlies the cooperative effects of Vhlh and Pten
mutation on S6 phosphorylation appears to be tissue specific,
as Cre-mediated deletion of Pten alone in mouse embryo fi-
broblasts (Fig. 11G) or in the kidney (data not shown) was
sufficient to induce phosphorylation of AKT and of S6 ribo-
somal protein in the absence of serum and this was not further
modified by combined deletion of Vhlh.
These findings suggest that pVHL normally functions in the
epididymis to suppress the activation of downstream compo-
nents of the PI3K signaling pathway. It is possible that pVHL
may therefore limit basal cell proliferation in response to Pten
mutation and PI3K and AKT activation. Combined mutation
of Vhlh and Pten may allow mTOR and p70S6K activation,
which may drive basal cell proliferation.
Elevated Notch signaling in tumors in Vhlh/ Pten/ mice.
A striking feature of tumors in all genital tract tissues in
Vhlh/ Pten/ mice is the presence of epidermis-like tissue
that arises from the normal simple epithelia that line these
tissues. Epidermal differentiation is normally regulated by
cross talk between the p63 transcription factor and the Notch
signaling pathway that ensures the correct balance between
keratinocyte self-renewal and differentiation (29). Notch
downregulates expression of p63 to allow keratinocyte terminal
differentiation, and p63 negatively regulates transcription by
Notch to inhibit its ability to induce keratinocyte differentia-
tion (29). Given that combined Vhlh and Pten deletion causes
expansion of p63-expressing basal cells and also leads to
HIF1 activation, it is noteworthy that HIF1 has been shown
to promote Notch signaling by binding to the cleaved Notch
intracellular domain at the promoters of Notch target genes,
inducing their expression (11). HIF1 has also been shown to
induce the expression of the Notch ligand Jag-2 (3). Finally,
expression of the active intracellular domains of either Notch1
or Notch4 in transgenic mice induces epididymal hyperplasia
(14, 23).
Given these connections between Notch, HIF, hyperpro-
liferation, and squamous differentiation, we investigated the
status of Notch signaling pathways in Vhlh/ Pten/ mice.
Real-time quantitative PCR analysis revealed upregulation of
mRNA expression of Notch3 and Notch4, but not Notch1 and
Notch2, in epididymides of Vhlh/ and Vhlh/ Pten/ mice
(Fig. 12A). Interestingly, epididymides of Vhlh/ Pten/
mice, but not those of the other genotypes, displayed increased
mRNA levels of the Notch ligands Delta-1 and Jag-2 (Fig. 12B)
as well as increased levels of the Notch target genes Hes-1,
Hey-1, and Hey-2 (Fig. 12C). These findings suggest that a
FIG. 9. Squamous differentiation in the epididymis of Vhlh/ Pten/ mice. Immunohistochemical staining was done for K6 (A to E) and
involucrin (F to J) in epididymides of wild-type (A and F), Vhlh/ (B and G), Pten/ (C and H), and Vhlh/ Pten/ (D, E, I, and J) mice. Panels
D and I display regions of squamous metaplasia (SM), and panels E and J display regions of cystadenoma (CA). All panels are the same
magnification. Bar, 50 m.
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combination of upregulation of Notch receptors and ligands
leads to activation of Notch signaling in Vhlh/ Pten/ mice.
While an antibody against the active intracellular domain of
Notch1 revealed staining in spermatocytes, as previously dem-
onstrated (28), no staining was observed within the tumor
tissue (data not shown), suggesting that Notch1 is not activated
in epididymides of Vhlh/ Pten/ mice. However, consistent
with mRNA analysis, immunohistochemical staining revealed
that Notch4 protein expression was upregulated and restricted
to regions of terminally differentiated squamous metaplasia in
Vhlh/ Pten/ mice (Fig. 12H). Interestingly, regions of squa-
mous differentiation in Vhlh/ Pten/ mice display high levels
of p63 in basal layers of cells and transient amplifying kerati-
nocyte-like cells, but p63 expression is absent in terminally
differentiated keratinocyte-like cells (Fig. 8E, arrowheads). In
the epidermis, similar downregulation of p63 expression is
mediated by Notch (16), supporting the notion that aberrant
Notch4 signaling may underlie the squamous differentiation in
Vhlh/ Pten/ mice.
DISCUSSION
Previous mouse models of Vhlh mutation surprisingly did
not develop the characteristic tumors that arise in human VHL
patients. However, subsequent careful analysis of VHL patient
tissue revealed that kidney, central nervous system, endolym-
phatic duct, and epididymal tissues all contain many sites of
VHL mutation but relatively few frank tumors, suggesting that
mutations in addition to VHL mutation may be required for
tumor formation (8, 25, 47, 48). In this study, we present proof
of concept of this idea of cooperative tumor suppression in
VHL disease. We describe a mouse model of VHL-associated
epididymal clear cell cystadenoma that results from combined
deletion of the Vhlh and Pten tumor suppressor genes.
FIG. 10. Activation of HIF activity in epididymal tumors in Vhlh/ Pten/ mice. (A to J) Immunohistochemical staining for HIF1 (A to E)
and HIF2 (F to J) in epididymal tubules of 8-week-old wild-type (A and F), Vhlh/ (B and G), Pten/ (C and H), and Vhlh/ Pten/ (D, E,
I, and J) mice. Panels D and I display regions of cystadenoma (CA), and panels E and J display regions of squamous metaplasia (SM). Panels A
to J are all at the same magnification. Bar, 50 m. (K) Real-time quantitative PCR analysis of mRNA expression in epididymides from 8- to
14-week-old wild-type, Vhlh/, Pten/, and Vhlh/ Pten/ mice, using specific primers for Glut-1 and Vegf-a. Expression changes were normalized
against the expression level of the 18S rRNA. Data represent means  standard deviations (n 	 2) or means  ranges (n 
 2). Each sample was
analyzed in triplicate. (L) Western blotting analysis of protein lysates of epididymides from two independent mice of each of the genotypes shown
in the figure. Blots were probed with antibodies against pVHL, PTEN, HIF2, LDH-A, GLUT-1, phospho-Ser473-AKT, AKT1, phospho-Ser240/
244 S6 ribosomal protein, and S6 ribosomal protein. Note that the apparent lack of decrease in PTEN expression in the second Vhlh/ Pten/
mouse (last lane) likely reflects the high stromal component of this particular tumor (data not shown). Stromal tissue, which is not subject to
Cre-mediated gene deletion, exhibits high PTEN expression (data not shown).
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Consistent with a previous study of VHL patients that dem-
onstrated that loss of pVHL function and HIF activation
alone are insufficient to induce the formation of frank epidid-
ymal cystadenoma (9), we found that deletion of Vhlh in the
epididymis and other genital tract epithelia in mice is sufficient
to activate HIF but does not induce epithelial cell prolifera-
tion. We show here that epididymal cystadenomas in human
VHL patients frequently display loss of PTEN expression,
which may contribute to tumor formation in these lesions.
Indeed, while deletion of Pten in the mouse genital tract
caused mild epithelial hyperplasia, combined deletion of Vhlh
and Pten together caused tumorigenic transformation. Clear
cell cystadenomas that histologically resemble the clear cell
cystadenomas that form in VHL disease patients arose in the
FIG. 11. Dysregulation of PI3K signaling in epididymal tumors in Vhlh/ Pten/ mice. (A) Western blotting analysis of protein lysates from
Fig. 10L, using antibodies against phospho-Ser473-AKT, AKT1, phospho-Ser240/244 S6 ribosomal protein, S6 ribosomal protein, phospho-Ser9
GSK3, and phospho-Thr202/Tyr204 ERK1/2. (B to F) Immunohistochemical staining for phospho-Ser240/244 S6 ribosomal protein in epididymal
tubules of 8-week-old wild-type (B), Vhlh/ (C), Pten/ (D), and Vhlh/ Pten/ (E and F) mice. Regions of cystadenoma (CA) and squamous
metaplasia (SM) are labeled. Bar, 50 m. (G) Western blotting analysis of protein lysates from wild-type, Vhlhfl/fl, Ptenfl/fl, and Vhlhfl/flPtenfl/fl mouse
embryonic fibroblasts, with or without infection with adenovirus expressing Cre and growth for 3 days in medium containing no serum. Blots were
probed with antibodies against pVHL, PTEN, phospho-Ser473-AKT, AKT1, phospho-Ser240/244 S6 ribosomal protein, and S6 ribosomal protein.
FIG. 12. Activation of Notch signaling in epididymal tumors in Vhlh/ Pten/ mice. (A to C) Real-time quantitative PCR analysis of mRNA
expression in epididymides from 8- to 14-week-old wild-type, Vhlh/, Pten/, and Vhlh/ Pten/ mice, using specific primers for Notch1, Notch2,
Notch3, and Notch4 (A), for Delta-1 and Jag-2 (B), and for Hes-1, Hey-1, and Hey-2 (C). Expression changes were normalized against the expression
level of the 18S rRNA. Data represent means  standard deviations (n 	 2) or means  ranges (n 
 2). Each sample was analyzed in triplicate.
(D to H) Immunohistochemical staining for Notch4 in epididymal tubules of 8-week-old wild-type (D), Vhlh/ (E), Pten/ (F), and Vhlh/ Pten/
(G and H) mice. Regions of cystadenoma (CA) and squamous metaplasia (SM) are labeled. Bar, 50 m.
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epididymal ducts, vas deferens, vesicular glands, endometrium,
and oviducts of Vhlh/ Pten/ mice. Another striking histo-
logical feature of tumors in Vhlh/ Pten/ mice is the pres-
ence of squamous differentiation that fully recapitulates the
structure of the epidermis. While lesions in VHL patients have
not been reported to involve squamous differentiation and we
did not observe markers of squamous differentiation in VHL
patient epididymal cystadenomas (data not shown), loss of
PTEN expression and activation of the PI3K signaling pathway
have been reported to occur in a variety of human squamous
cell carcinomas (32, 39, 43).
What causes genital tract epithelia to be reprogrammed to
form cystadenomas and epidermis-like structures upon Vhlh
and Pten deletion? Part of the answer to this question likely lies
in the dramatically increased number of basal cells in tumors of
Vhlh/ Pten/ mice. One possible signaling cascade that may
regulate basal cell proliferation is the PI3K pathway. Several
studies (reviewed in reference 44) have demonstrated that
PI3K, AKT, and mTOR activities are necessary for mainte-
nance and proliferation of stem and progenitor cells and that
loss of PTEN leads to enhanced stem cell proliferation and
expansion of tissue progenitor cells, including basal cells of the
prostate (49). In this respect, we uncovered a cooperative role
of Vhlh and Pten mutation in inducing the phosphorylation of
ribosomal protein S6, a downstream effector of the PI3K-
mTOR-S6K signaling pathway. The presence of Vhlh may
thereby limit basal cell expansion in Pten mutant mice. How-
ever, Pten deletion in the absence of Vhlh leads to high levels
of mTOR and S6K signaling, which may then drive the ob-
served uncontrolled basal cell proliferation. The molecular
nature of this genetic cooperation remains unclear and appears
to be tissue specific. One possible mechanism that may apply to
the epididymis may be that loss of pVHL leads to HIF-
mediated upregulation of growth factors, such as platelet-de-
rived growth factor and transforming growth factor alpha, that
could act in an autocrine or paracrine fashion on Pten-deficient
cells to hyperactivate signal transduction through the PI3K-
AKT-mTOR-S6K signaling cascade.
Another signaling pathway that may be relevant to tumor
formation in the mouse model is the Notch pathway. Tumors
of Vhlh/ Pten/ mice displayed upregulation of mRNAs
encoding the Notch3 and Notch4 receptors and the Notch
ligands Delta-1 and Jag-2 and of several Notch-inducible target
genes, suggesting that combined Vhlh and Pten deletion leads
to aberrant Notch activity in genital epithelia. Since Notch
signaling in keratinocytes promotes epidermal differentiation
(22, 30, 35), we reasoned that aberrant Notch activation might
contribute to the squamous differentiation phenotype of
Vhlh/ Pten/ mice. Indeed, we observed specific expression
of Notch4 in regions of squamous differentiation. Thus, the
epididymides of Vhlh/ Pten/ mice reproduce at least two
key elements that normally underlie the differentiation of the
epidermis: the expanded population of p63-expressing basal
cells may function analogously to the p63-expressing basal cells
in the epidermis and may be acted upon by aberrant Notch4
signaling, resulting in squamous differentiation.
As discussed by Gla¨sker et al. (9), the tissue type of origin of
cystadenomas in VHL patients is controversial, with various
studies proposing different mesonephric duct-derived tissue,
including the epididymal ducts, efferent ductules, vas deferens,
testicular appendix, epididymal appendix, and paradidymis.
Our findings may reconcile these observations. Since deletion
of Vhlh and Pten in the mesonephric duct of mice induces
cystadenoma formation in diverse genital tract tissues, it is
possible that cystadenomas in VHL patients could form in all
of the above-mentioned tissues. Slightly different molecular
and cellular events may underlie tumorigenesis at different
sites. For example, while tumors derived in mice are charac-
terized by an expansion of basal cells, analysis of three epidid-
ymal cystadenomas from human VHL patients did not reveal
p63-positive cells (data not shown). This finding is not unex-
pected, as these particular tumors are likely to have arisen
from efferent ductules (9), an epithelium that is not character-
ized by the presence of basal cells. It will be interesting in
further studies to analyze the activation status of the PI3K
signaling pathway and of pathways including p63 and Notch in
a larger sample of tumors from different mesonephric duct-
derived tissues in VHL patients. The awareness that lesions in
VHL patients may potentially occur at sites in the genital tract
in addition to the epididymis may translate into improved
diagnosis for these patients.
In summary, our study provides evidence that additional
mutations can cooperate with loss of VHL function in tumor-
igenesis and suggests that mutations that lead to activation of
the PI3K signaling pathway may contribute to the pathology of
genital tract tumors associated with VHL deficiency. Since
inheritance of VHL mutations predisposes patients to the de-
velopment of a variety of tumors, including renal cell carci-
noma, it is tempting to speculate that mutations that activate
the PI3K pathway may contribute to tumor progression more
generally in VHL disease. If so, our study suggests that drugs
that interfere with the active PI3K signaling pathway may po-
tentially be of therapeutic benefit in genital tract lesions and
other cancers that involve VHL mutation.
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